https://doi.org/10.55788/7575102f
Obinutuzumab is a type 2, optimised, anti-CD20 monoclonal antibody that kills B cells effectively. The recently published, double-blind, phase 2 NOBILITY study (NCT02550652) randomised patients with lupus nephritis 1:1 to either 100 mg of obinutuzumab (n=63) or placebo (n=62) [1,2]. Doses were administered at weeks 0 and 2, followed by doses at weeks 24 and 26. Both groups continued with the standard of care, which included a mycophenolate-based lupus regimen. Complete renal response (CRR) was significantly improved in the obinutuzumab group up to 2 years later [1].
Dr Brad Rovin (Ohio State University, OH, USA) and colleagues presented a post hoc analysis of NOBILITY, investigating other kidney outcomes [2]. This included the time to first unfavourable kidney outcome and eGFR slope between week 12 and week 104.
Unfavourable kidney outcomes were reduced in the obinutuzumab group (HR 0.40; 95% CI 0.20–0.80). The adjusted mean difference in eGFR at 2 years was 9.7 mL/min/1.73 m2 (95% CI 1.7–18; P=0.017), favouring the obinutuzumab group. Obinutuzumab annual slope difference of eGFR was -0.43 (95% CI -3.16 to 2.31); this was -4.52 (95% CI -7.41 to -1.66) for placebo.
While Dr Rovin noted that these data should be viewed cautiously since they are post hoc and that the work needs to be tested prospectively, he concluded that “these data suggest better long-term preservation of kidney function with obinutuzumab.” The phase 3 REGENCY trial (NCT04221477) will prospectively evaluate obinutuzumab for lupus nephritis, and it has finished recruiting.
- Furie RA, et al. Ann Rheum Dis. 2022 Jan;81(1):100-107.
- Rovin B, et al. Kidney-Related Outcomes in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of the Phase 2 NOBILITY Trial. TH-OR30, ASN Kidney Week 2023, 2–5 November, Philadelphia, PA, USA.
Copyright ©️2023 Medicom Medical Publishers
Posted on
Previous Article
« Clinical benefits of sparsentan for patients with FSGS Next Article
RMC-035 reduces long-term adverse kidney events following cardiac surgery »
« Clinical benefits of sparsentan for patients with FSGS Next Article
RMC-035 reduces long-term adverse kidney events following cardiac surgery »
Table of Contents: ASN 2023
Featured articles
Patient care technicians improve haemodialysis patient outcomes
Sparsentan outperforms irbesartan for treatment of IgAN
Chronic Kidney Disease
Aldosterone synthase inhibition reduces albuminuria in CKD
Low doses of zibotentan with dapagliflozin improve albuminuria in patients with CKD
Spironolactone failed to reduce major adverse cardiac effects in patients with CKD on haemodialysis
Efficacy of bardoxolone methyl for DKD, without increased cardiac risk
Renal Replacement Therapy
New approaches to successful vascular access
Patient care technicians improve haemodialysis patient outcomes
Donor stem cells may reduce lifelong immunosuppressant use following transplant surgery
A systems approach to kidney transplantation disappoints
Glomerular Disease
Obinutuzumab attenuates kidney decline in lupus nephritis
Clinical benefits of sparsentan for patients with FSGS
Sparsentan outperforms irbesartan for treatment of IgAN
Rare or Genetic Kidney Disease
Small molecule PGE1 shows promise for nephronophthisis treatment in vitro and in vivo
Related Articles
May 21, 2019
Renal transplantation
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com